Literature DB >> 30743190

Does influenza vaccination or RSV prophylaxis impact resource utilization for children after the diagnosis of airway disorders?

Jeffrey Cheng1, Congwen Zhao2, Hui-Jie Lee2.   

Abstract

OBJECTIVE: Quantify the rates influenza vaccination and RSV prophylaxis for children with airway stenosis and/or other disorders and assess impact on resource utilization.
METHODS: This was a retrospective study with data extracted from Duke Enterprise Data Unified Content Explorer (DEDUCE) between January 1, 2006 and December 1, 2017. Children aged 18 years and younger with at least one diagnosis code for airway stenosis and/or disorders were included. The index date was defined as the first date of airway stenosis/disorders diagnosis. Each patient was followed for up to one year after the index date. Influenza vaccination or RSV prophylaxis documented within one year of index date were included. We defined emergency department (ED) visits and/or hospital admissions related to respiratory diagnoses as the primary outcome of increased resource utilization.
RESULTS: A total of 2718 patients were included. In our institution, our results have indicated that there are fairly low vaccination documentation rates of influenza vaccination, RSV prophylaxis, or both provided to children with airway stenosis/disorders, 14.1% (389/2718), 1.1% (30/2718), and 0.6% (17/2718), respectively, within the first year after diagnosis. Around 5% (139/2718) and 10% (269/2718) experienced ED visits or hospitalizations related to respiratory issues within the first year after diagnosis, respectively. Among 139 and 269 patients with ED visits or hospitalizations, 34 (25%) and 54 (20%) had multiple visits, respectively. Very few patients had documented influenza vaccination (11/139, 0.4%) or RSV prophylaxis (5/269, 0.18%) before ED visits or hospitalization.
CONCLUSIONS: There is little available evidence at this time for strategies to prevent adverse events or complications in children with airway stenosis/disorders. In our institution, our results have indicated that there are fairly low documented rates of influenza vaccination, RSV prophylaxis, or both provided to children with airway stenosis/disorders in the first year after diagnosis. This is an area of significant clinical interest for potentially limiting adverse events and optimizing resource utilization for children with airway stenosis/disorders.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Airway disorders; Influenza; Palivizumab; Pediatric; RSV; Subglottic stenosis

Mesh:

Substances:

Year:  2019        PMID: 30743190      PMCID: PMC6440862          DOI: 10.1016/j.ijporl.2019.02.013

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  7 in total

Review 1.  The potential impact of palivizumab on pediatric airway reconstruction.

Authors:  Kevin Emerick; Michael Cunningham; Christopher Hartnick
Journal:  Am J Otolaryngol       Date:  2006 Jan-Feb       Impact factor: 1.808

Review 2.  Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.

Authors:  D Wang; S Bayliss; C Meads
Journal:  Health Technol Assess       Date:  2011-01       Impact factor: 4.014

3.  Resource utilization in the management of subglottic stenosis.

Authors:  Rahul K Shah; Lina Lander; Sukgi S Choi; George H Zalzal
Journal:  Otolaryngol Head Neck Surg       Date:  2008-02       Impact factor: 3.497

Review 4.  Systematic review of the cost-effectiveness of influenza immunization programs.

Authors:  Eon E K Ting; Beate Sander; Wendy J Ungar
Journal:  Vaccine       Date:  2017-03-09       Impact factor: 3.641

5.  Vaccine for prevention of mild and moderate-to-severe influenza in children.

Authors:  Varsha K Jain; Luis Rivera; Khalequ Zaman; Roberto A Espos; Chukiat Sirivichayakul; Beatriz P Quiambao; Doris M Rivera-Medina; Pirunghul Kerdpanich; Mehmet Ceyhan; Ener C Dinleyici; Alejandro Cravioto; Mohammed Yunus; Pornthep Chanthavanich; Kriengsak Limkittikul; Zafer Kurugol; Emre Alhan; Adrian Caplanusi; Serge Durviaux; Philippe Boutet; Opokua Ofori-Anyinam; Vijayalakshmi Chandrasekaran; Ghassan Dbaibo; Bruce L Innis
Journal:  N Engl J Med       Date:  2013-12-11       Impact factor: 91.245

6.  Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  2014-08       Impact factor: 7.124

Review 7.  Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.

Authors:  Edward Gibson; Najida Begum; Birgir Sigmundsson; Alfred Sackeyfio; Judith Hackett; Sankarasubramanian Rajaram
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.